Talazoparib
Talazoparib is the most potent PARP trapper, approved in BRCA breast cancer and with enzalutamide in prostate cancer.
EMBRACA (gBRCA HER2- metastatic breast), TALAPRO-2 (with enzalutamide in mCRPC; HRR-mutant label 2023, OS benefit 2024-25). Pfizer.
1.Talazoparib traps PARP1 on DNA about 100-fold more potently than olaparib
- Route
- Oral
- Schedule
- 1 mg once daily (breast); 0.5 mg once daily with enzalutamide (prostate)
- Dose modifications
- 0.75 mg for moderate renal impairment; hold for grade ≥3 cytopenias
- Monitoring
- Blood counts monthly
Source: www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications. Doses are for orientation; the current label governs.
- Medicare
- Part D (self-administered)
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
- Commercial insurance
- covered with prior authorisation
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Germline BRCA (breast) or HRR gene alteration (prostate, with enzalutamide).
- Assistance programmes
- Pfizer Oncology Together
- Pfizer RxPathways
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
- Notes
- Licensed 2019 for germline BRCA HER2-negative breast cancer; NICE recommended it in 2024-25 with a commercial arrangement. TA number not verified. mCRPC with enzalutamide appraised separately.
Sources: NICE search: talazoparib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
- 16 Oct 2018ApprovalUS
gBRCA HER2-negative locally advanced/metastatic breast cancer (EMBRACA) source
- 20 Jun 2023ApprovalUS
HRR-mutant mCRPC with enzalutamide (TALAPRO-2) source
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2018 | gBRCA HER2- locally advanced/metastatic breast cancer |
| US | 2023 | HRR-mutant mCRPC with enzalutamide |
| Adverse event |
|---|
| Anaemia |
| Fatigue |
| Nausea |
| Neutropenia |
| Thrombocytopenia |
| Headache |
| Alopecia |
EMBRACA: 53% any grade, 39% grade 3-4. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | not disclosed | pfizeroncologytogether.com |
| United Kingdom | NICE: recommended for gBRCA HER2-negative advanced breast cancer (TA952) and with enzalutamide in HRR-mutant mCRPC (2024) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Talazoparib" OR ABSTRACT:"Talazoparib" OR TITLE:"Talzenna" OR ABSTRACT:"Talzenna") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Talazoparib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductNiraparib
Shares PARP inhibitor + AR pathway inhibitor (prostate), Base excision repair, PARP & alkylation damage, Androgen receptor signalling, DNA damage response & homologous recombination.
- ProductRucaparib
Shares Base excision repair, PARP & alkylation damage, Double-strand break repair: HR versus end joining, PARP inhibitors, PARP.
- ProductOlaparib
Shares PARP inhibitor + AR pathway inhibitor (prostate), Iniparib, Base excision repair, PARP & alkylation damage, Androgen receptor signalling.
- TechnologyHRD & BRCA testing
Shares DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining, PARP.
- TargetATR
Shares Base excision repair, PARP & alkylation damage, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining.
- TechnologyPARP PET
Shares Base excision repair, PARP & alkylation damage, DNA damage response & homologous recombination, PARP, Triple-negative breast cancer (TNBC).
- PathwayDNA replication stress
Shares Base excision repair, PARP & alkylation damage, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining.
- PersonAlan Ashworth
Shares PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).